Most Recent
The only female partner at global technology research firm Information Services Group has sued her employer for alleged sex discrimination and harassment, saying the company is a “hostile environment” for senior women employees.
The Daily Mail is appealing a judge’s decision to award Nine sports presenter Erin Molan $150,000 over an article concerning an on-air remark she made about the pronunciation of National Rugby League Polynesian player names.
Vocational education provider Box Hill Institute has reached an in-principle settlement in a class action by disgruntled students who allege the licences they obtained through the institute did not provide them with the requisite knowledge or training to obtain a commercial pilot's licence.
Aussie Home Loans is facing a class action investigation for allegedly selling “essentially worthless” policies to homeowners.
A judge has ordered two Sydney roof tiling businesses and their directors to pay a total of $420,000 in penalties after making admissions in proceedings brought by the Australian Competition and Consumer Commission alleging they rigged bids for construction at the University of Sydney.
Nine Network has apologised to former member for Bowman, Andrew Laming, over a news segment that accused him of taking a lewd photograph, having struck a confidential settlement after the broadcaster dropped all defences to the politician's defamation case.
Senior lawyers for Star Entertainment have been called out by the NSW gambling regulator for gumming up investigations with unfounded claims of legal professional privilege and misleading the National Australia Bank about transactions that used China Union Pay debit cards.
A law firm whose principal has been barred from practicing has been restrained from obstructing a Thomson Geer partner appointed to manage it.
A judge has called off a pre-trial hearing to determine whether the new serious harm element in Australia's defamation laws is satisfied in a case brought by a weight lifting coach, citing an “unfortunate turn of events".
German biotech Fresenius Kabi has struck back at Samsung Bioepis's latest attack on the validity of its patents for a liquid formulation of top selling immunosuppressant drug Humira, accusing the Korean company of causing its sales to flag by infringing the patent.